Genotype/Phenotype Interactions and First Steps Toward Targeted Therapy for Sphingosine Phosphate Lyase Insufficiency...

Area of Science:

• Biochemistry
• Genetics
• Rare metabolic disorders

Background:

• Sphingosine-1-phosphate lyase insufficiency syndrome (SPLIS) results from SGPL1 gene mutations, impairing sphingolipid metabolism.
• This leads to sphingolipid intermediate accumulation and lymphopenia, with other symptoms like nephrotic syndrome and neuronal defects.
• The pathogenesis of non-lymphopenic symptoms and genotype-phenotype correlations are not fully understood.

Purpose of the Study:

• To investigate the correlation between SGPL1 genotypes, age at diagnosis, and patient outcomes in SPLIS.
• To evaluate the potential of vitamin B6 supplementation and gene therapy as therapeutic strategies for SPLIS.

Main Methods:

• Analysis of SGPL1 genotypes and their correlation with clinical presentation and patient outcomes.
• Assessment of vitamin B6 supplementation efficacy in a subset of patients.
• Evaluation of adeno-associated virus (AAV)-mediated SGPL1 gene therapy in Sgpl1 knockout (SPL^KO) mouse models of SPLIS.

Main Results:

• Vitamin B6 supplementation shows limited efficacy, benefiting only patients with susceptible alleles.
• AAV-mediated SGPL1 gene therapy in SPL^KO mice demonstrated significant improvements in survival, kidney, and neurological function.
• Gene therapy offers a potential universal treatment for various types of SGPL1 mutations.

Conclusions:

• Gene therapy is a promising, potentially curative treatment for SPLIS, addressing a wide range of mutations.
• Further research into the pathogenesis of non-lymphopenic symptoms is warranted.
• Targeted therapies like gene therapy offer hope for patients with this rare metabolic disorder.